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Rheumatoid arthritis (RA) is a systemic autoimmune disease whose main feature is 39 
persistent joint inflammation. Toll-like receptors (TLRs) play critical roles in the 40 
activation of innate and adaptive immune responses, and influence the activity of NFB, 41 
a key player in chronic inflammation. We aimed at investigating the association of TLR 42 
allelic variants with susceptibility and severity of RA through a systematic, high-43 
throughput, analysis of TLR genes. All coding exons and flanking regions of nine 44 
members of the TLR family (TLR1-9) were analyzed in 66 patients with RA and 30 45 
healthy controls by next generation sequencing. We focussed on three single allelic 46 
variants, N248S in TLR1, Q11L in TLR7 and M1V in TLR8 based on the allelic 47 
frequencies in both patient and control populations, the predicted impact on protein 48 
function and the novelty in RA research. Analysis of these selected variants in a larger 49 
cohort of 402 patients with RA and in 208 controls revealed no association with 50 
susceptibility. However, the M1V allele was associated with a lower need for disease-51 
modifying antirheumatic drugs (DMARDs) (p=0,008) and biologic treatments (p=0,021). 52 
Functional studies showed that the M1V variant leads to a reduced production of 53 
inflammatory cytokines, IL-1, IL-6 and TNF, in response to TLR8 agonists. Thus, the 54 
presence of this variant confers a significant protective effect on disease severity. These 55 
results show for the first time the association between the M1V variant of TLR8 and 56 
reduced disease severity in RA, which could have prognostic value for these patients. 57 
  58 





1. Introduction 62 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease caused by the 63 
chronic inflammation of the synovial lining. It is characterized by progressive joint 64 
destruction [1]. Although a number of genes have been identified as possible targets in 65 
this pathology, the genetic regulation that contributes to the development and progression 66 
of disease in RA patients remains unclear [2]. It has been suggested that viruses and 67 
bacteria may contribute to initiate or exacerbate RA by binding to Toll-like receptors 68 
(TLRs) [3-4]. TLRs constitute a family of transmembrane proteins whose activation has 69 
been implicated in the loss of self-tolerance leading to autoimmunity and chronic 70 
inflammation [5-7]. They play an essential role in the activation and regulation of innate 71 
and acquired immune responses through recognition of specific pathogen-associated 72 
molecular patterns and endogenous peptides [6,8]. The stimulation of the TLR pathway 73 
modulates NFB activation and thus the production of proinflammatory cytokines and 74 
cell-adhesion molecules [9-10]. Activation of the NFB pathway plays a key role in the 75 
pathogenesis of chronic inflammatory diseases, including RA and inflammatory bowel 76 
disease [11]. The most recently described TLRs involved in responding to viral 77 
stimulation are TLR7 and TLR8. They are located at the membranes of the endosomal 78 
compartment and recognize viral single-stranded RNA and short double-stranded RNA 79 
[12-13]. Human TLR8 is expressed in monocytes/macrophages and myeloid dendritic 80 
cells [14]. TLR8 signaling is mediated by the adaptor protein MyD88 which activates 81 
NFB, IRF-7 and p38 MAPK, resulting in the induction of proinflammatory cytokines 82 
and tissue-destructive enzymes [15]. TLR8 is located on the X chromosome and spans 83 
15.5 kb (Xp22.3-p22.2). At the genomic level, two splice variants with alternative 84 
translation start sites, due to SNP rs3764880 (p.Met1Val), are encoded by TLR8 gene 85 
(TLR8v1 and TLR8v2) [16-17]. Although TLR8v2, that lacks the first three amino acids, 86 
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is the most conserved isoform of TLR8 among primates, the long isoform (TLR8v1) plays 87 
a major role in the positive regulation of TLR8 function in differentiated monocytes [18]. 88 
Genetic variants in TLRs have been mainly associated with disease susceptibility in 89 
patients with RA with variable level of significance and even discordant results [5,19-90 
22]. Although several polymorphisms of TLR8 have been studied in RA patients, only 91 
rs5741883 has shown a moderate association with rheumatoid factor (RF) positivity 92 
[5,23].  93 
In this study, we analyzed the association of variants N248S in TLR1, Q11L in TLR7 and 94 
M1V in TLR8 in 402 patients with RA and showed that M1V variant is significantly 95 
associated with a reduced need for disease-modifying antirheumatic drugs (DMARDs) 96 
and biologic treatment. We also described that monocytes from M1V variant carriers had 97 
a reduced production of inflammatory cytokines, IL-1, IL-6 and TNF, in response to 98 
TLR8 agonists.  99 
  100 
2. Materials and methods 101 
2.1. Patient samples 102 
A first cohort of 66 selected RA patients with high disease severity (RF and/or ACCP 103 
positivity, erosive disease and failure to at least one DMARD) and 30 healthy controls 104 
were enrolled for next-generation sequencing (NGS). Identified variants were analyzed 105 
in a second cohort of 402 unselected patients with RA (Table 1), diagnosed according to 106 
the 1987 American College of Rheumatology (ACR) classification criteria [24].  107 
Table 1. Main features of the patients  108 
 109 
Female sex, %  72.9 110 
Mean age ± SD, years 65.99 ± 14.20 111 
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Mean duration of follow-up ± SD, months  124.76 ± 91.27 112 
Extra-articular manifestations, %  23.1 113 
Erosive disease, %  57.7 114 
RFa positive, %  63.7 115 
Patients (%) treated with: 116 
 DMARDs  97.6 117 
 Corticoid therapy  59.9 118 
 Biologic therapy  37.0 119 
Mean number of DMARDs ± SD 2.22 ± 1.48 120 
Mean number of biologics ± SD 1.81 ± 1.21 121 
aRF, rheumatoid factor.  122 
In this retrospective cohort study, anonimyzed clinical, laboratory and treatment data 123 
were registered, annotating RF or ACCP positivity and the number of DMARDs and 124 
biologics. As a control population, 208 sex and age matched individuals who had no 125 
known history of serious disease, including autoimmune or chronic inflammatory 126 
disorders, were also genotyped. All patients were followed at Hospital Universitario 127 
Marques de Valdecilla (HUMV) (Santander, Spain) or Hospital Universitario La Paz 128 
(Madrid, Spain). Clinical information, including demographic data, disease 129 
characteristics, and treatment, has been previously described [25]. The study was 130 
approved by the corresponding Research Ethics Committees and informed consent was 131 
obtained from all subjects.  132 
2.2. Sequencing analyses 133 
The coding exons and flanking regions of the TLR family (TLR1-9) gene were sequenced 134 
in 66 RA patients and 30 healthy controls by NGS. DNA libraries were processed for 135 
hybrid enrichment using a custom SeqCap EZ design (Roche Nimblegen, Basel, 136 
Switzerland) containing the coding sequences of TLRs. Then, double barcoded libraries 137 
were sequenced by using a MiSeq NGS platform (Illumina, Madison, WI). Allelic 138 
variants were analyzed in other 402 patients with RA and 208 age-matched control 139 
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individuals by NGS sequencing. DNA was extracted from whole blood by using the 140 
QIAamp DNA blood kit (Qiagen, Hamburg, Germany) and amplified with primers for 141 
human TLR8 5’-CTCTTCTCGGCCACCTCCTG-3’ and 5’-142 
GCAAGCCGCTTTACCTGCAT-3’, TLR7 5’-GGGGTTGGGGATGCTGTTTA-3’ and 143 
5’-TGCAGTCCACGATCACATGG-3’, and TLR1 5’-144 
ATGCCAAACCAGCTGGAGGA-3’ and 5’-CCCTGAGGGCCTTCAAGACT-3’.  145 
2.3. Expression analyses of NFB target cytokines 146 
TLR8 activity was assessed by measuring the production of intracellular cytokines in 147 
monocytes as previously described [26]. Briefly, blood cells were stimulated with the 148 
TLR8 agonist ssRNA40 (InvivoGen, San Diego, CA) for 18 h in the presence of brefeldin 149 
A (Sigma-Aldrich, St Louis, MO) to prevent cytokine release. Cells were then stained 150 
with FITC-conjugated anti-human CD14 (BD Biosciences, San Jose, CA) to identify the 151 
monocyte population. Erythrocytes were lysed with FACS lysing solution (BD 152 
Biosciences). Mononuclear cells were permeabilized and intracellularly stained with 153 
phycoerythrin (PE)-labelled monoclonal antibodies against IL-1, TNF or IL-6 (BD 154 
Biosciences). Cytokine expression was analyzed by flow cytometry using Cell Quest Pro 155 
Software (BD Biosciences). 156 
2.4. Statistical analysis 157 
All statistical analyses were performed using SPSS 20 program (IBM, Armonk, NY). 158 
Differences in quantitative variables between groups of patients were compared with the 159 
Mann-Whitney U test, and the chi-squared statistic was used for categorical variables.  160 
For functional studies, the statistical comparisons of data between genotypes were 161 





3. Results 165 
Genetic variants within human TLR genes have been reported to be associated with 166 
susceptibility to RA with variable level of significance and even discordant results. We 167 
aimed to assess whether TLR variants contribute to modify the course of the disease in 168 
RA patients. To approach this goal, we sequenced the coding exons of nine members of 169 
the TLR family (TLR1-9) gene in 66 selected patients with RA and 30 healthy controls. 170 
A total of 71 variants were identified (Table 2).  171 
Table 2. Allelic variants of TLR genes in control and RA populations.  172 




P value AAb 
change 
Impact 
TLR1 rs113706342 0 0,007576 0,4991 H720P MODERATEc 
TLR1 rs41311400 0 0,007576 0,4991 G676G LOWd 
TLR1 rs151036585 0 0,007576 0,4991 D605Y MODERATE 
TLR1 rs5743618 0,4333 0,3333 0,1821 S602I MODERATE 
TLR1 rs5743614 0,3929 0,254 0,05834 S506S LOW 
TLR1 rs201398822 0,01667 0 0,137 L371F MODERATE 
TLR1 rs184548723 0 0,007576 0,4991 T363M MODERATE 
TLR1 rs3923647 0,01667 0,01515 0,9375 H305L MODERATE 
TLR1 rs4833095 0,4333 0,303 0,07807 N248S MODERATE 
TLR1 rs5743611 0,05 0,09091 0,3276 R80T MODERATE 
TLR1 rs145135062 0 0,007576 0,4991 I57M MODERATE 
TLR1 rs5743610 0,01667 0,01515 0,9375 H38H LOW 
TLR2 rs5743697 0 0,007576 0,4991 G38G LOW 
TLR2 rs200686000 0 0,007576 0,4991 T138I MODERATE 
TLR2 rs3804099 0,5167 0,4621 0,4831 N199N LOW 
TLR2 rs5743698 0 0,007576 0,4991 L213L LOW 
TLR2 rs3804100 0,06667 0,08333 0,69 S450S LOW 
TLR2 rs5743700 0,05 0,02273 0,3141 F541F LOW 
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TLR2 rs5743704 0,01667 0,02273 0,7852 P631H MODERATE 
TLR2 rs5743708 0 0,007576 0,4991 R753Q MODERATE 
TLR3 rs3775291 0,4333 0,3409 0,2188 L135F MODERATE 
TLR3 rs3775290 0,3333 0,3258 0,9175 F182F LOW 
TLR3 rs73873710 0,06667 0,02273 0,1321 F574F LOW 
TLR4 rs78848399 0,01667 0 0,137 Y46C MODERATE 
TLR4 rs137853920 0,05 0,01515 0,1599 C241Y MODERATE 
TLR4 rs4986790 0,1 0,06061 0,3305 D259G MODERATE 
TLR4 rs56070048 0 0,007576 0,4991 K314K LOW 
TLR4 rs4986791 0,1 0,06061 0,3305 T359I MODERATE 
TLR4 rs5030721 0,01667 0,0303 0,5824 K613K LOW 
TLR4 rs5030724 0,01667 0 0,137 Q794K MODERATE 
TLR5 rs1053954 0,08333 0,07576 0,8561 K841K LOW 
TLR5 rs7512943 0 0 NA F822L MODERATE 
TLR5 rs5744174 0,3333 0,3333 1 F616L MODERATE 
TLR5 rs2072493 0,1667 0,2652 0,1354 N592S MODERATE 
TLR5 rs5744169 0 0,007576 0,4991 L444L LOW 
TLR5 rs5744168 0,01667 0,007576 0,5652 R392* HIGHe 
TLR5 rs45528236 0,01667 0,007576 0,5652 Q181K MODERATE 
TLR5 rs764535 0,01667 0 0,137 T82I MODERATE 
TLR5 rs5744165 0,03333 0,03788 0,8762 V61V LOW 
TLR5 rs187499609 0 0,007576 0,4991 R34H MODERATE 
TLR6 rs138342666 0,01667 0,02273 0,7852 I461V MODERATE 
TLR6 rs5743820 0,03333 0,007576 0,1822 T440M MODERATE 
TLR6 rs5743818 0,2167 0,2424 0,6961 A644A LOW 
TLR6 rs5743816 0,01667 0 0,137 V465I MODERATE 
TLR6 rs5743815 0,01667 0,0303 0,5824 V427A MODERATE 
TLR6 rs3775073 0,3 0,3182 0,8011 K421K LOW 
TLR6 rs3821985 0,3167 0,303 0,8494 T361T LOW 
TLR6 rs5743810 0,35 0,3712 0,7771 S249P MODERATE 
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TLR6 rs189784331 0 0,01515 0,3378 V213V LOW 
TLR7 rs179008 0,3167 0,197 0,06955 Q11L MODERATE 
TLR7 rs55907843 0 0,007576 0,4991 V222D MODERATE 
TLR7 rs5743780 0 0,02273 0,2392 L345L LOW 
TLR7 rs5743781 0 0,0303 0,173 A448V MODERATE 
TLR7 rs864058 0,15 0,08333 0,161 T801T LOW 
TLR7 rs141270925 0 0,01515 0,3378 Y897Y LOW 
TLR7 rs189681811 0 0,007576 0,4991 R920K MODERATE 
TLR8 rs3764880 0,3667 0,2424 0,07593 M1V HIGH 
TLR8 rs56194919 0,01667 0,0303 0,5824 C25C LOW 
TLR8 rs2159377 0,2 0,1894 0,8629 D118D LOW 
TLR8 rs5744080 0,35 0,3636 0,8552 H215H LOW 
TLR8 rs2407992 0,4 0,3636 0,6295 L651L LOW 
TLR8 rs3747414 0,3 0,2803 0,7796 I751I LOW 
TLR8 rs2109135 0 0 NA D923D LOW 
TLR9 rs445676 0,03333 0,02308 0,6814 Y980Y LOW 
TLR9 rs5743845 0 0,007576 0,4991 R863Q MODERATE 
TLR9 rs352140 0,4833 0,4848 0,9845 P545P LOW 
TLR9 rs141799890 0 0,007576 0,4991 H539Q MODERATE 
TLR9 rs35342983 0 0,007576 0,4991 S509S LOW 
TLR9 rs35654187 0 0,007576 0,4991 T383T LOW 
TLR9 rs150459369 0,01667 0,007576 0,5652 A7T MODERATE 
TLR9 rs5743842 0,01667 0 0,137 R5C MODERATE 
aMAF, minor allele frequency; bAA, amino acid; cnon-disruptive variant that might 173 
change protein effectiveness, dmostly harmless or unlikely to change protein behaviour, 174 
eassumed to have high or disruptive impact in the protein, probably causing protein 175 
truncation or loss of function.  176 
Three variants, N248S in TLR1, Q11L in TLR7 and M1V in TLR8 genes were selected 177 
based on the allelic frequencies in both patient and control populations, the novelty in RA 178 
research and the predicted functional impact on the protein as assessed by using 179 
PolyPhen, SIFT and SNPs3D programs. We studied these variants in a larger cohort of 180 
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402 patients with RA and in 208 controls and showed that none of them was associated 181 
with disease susceptibility as the genotypes distribution was similar in both patient and 182 
control populations (Table 3).  183 
Table 3. Genotype frequencies of selected TLR variants in controls and RA patients.  184 
Variant Genotype Controls % Cases % P value ORa (95% CIb) 
TLR1-N248S TT 0.35 0.36   
TLR1-N248S TC 0.46 0.48 0.900 1.032 (0.636-1.672) 
TLR1-N248S CC 0.18 0.14 0.461 0.788 (0.417-1.487) 
TLR7-Q11L AA 0.64 0.69   
TLR7-Q11L AT 0.29 0.20 0.906 0.660 (0.399-1.095) 
TLR7-Q11L TT 0.05 0.09 0.350 1.539 (0.620-3.822) 
TLR8-M1V AA 55.7 55.7   
TLR8-M1V AG 30.6 30.1 0.941 0.982 (0.608-1.585) 
TLR8-M1V  GG 13.9 14.2 0.957 1.018 (0.539-1.923) 
aOR, odds ratio; bCI, confidence interval 185 
Then we analyzed a number of clinical findings associated with disease severity. 186 
Interestingly, we found that the presence of two copies of the G allele of TLR8 gene 187 
tended to correlate with clinical remission, better prognosis (less surgical interventions 188 
and prostheses), lower need for pharmacological therapies and the absence of two well-189 
known serological markers of disease severity, RF and  ACCP (Fig. 1A). Furthermore, 190 
when we analyzed the need for disease-modifying antirheumatic drugs (DMARDs) and 191 
biologic therapy among GG (homozygotes for the V variant) and AG/AA genotype 192 
carriers, we showed that the GG genotype was significantly associated with lower number 193 
of  DMARDs  (p=0,008) and biologics (p=0,021) (Fig. 1B and 1C). Thus, this variant 194 
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appears to select a group of patients with less severe and refractory disease. In order to 195 
correlate these data with the level of inflammatory mediators, we stimulated patient blood 196 
cells with a TLR8 agonist and analyzed the production of inflammatory cytokines by flow 197 
cytometry. As shown in Fig. 2, IL-1β, TNF-α and IL-6 levels in circulating monocytes 198 
were lower in GG genotype carriers compared with those in patients carrying the AA 199 
genotype. Although these differences did not reach statistical significance, most likely 200 
because of the low frequency of the rare allele, the results are consistent with our previous 201 
data and strengthen the association of the GG genotype with a reduced inflammatory 202 
response following activation of TLR8. 203 
 204 
4. Discussion 205 
TLR8 variants have been associated with susceptibility to infectious and autoimmune 206 
diseases including tuberculosis and systemic lupus erythematosus [27-29]. In this study, 207 
we show that M1V variant of TLR8 is associated with disease severity in RA, and selects 208 
a group of patients with a lower need for therapeutic interventions. A meta-analysis that 209 
included 14 studies worldwide has been recently performed to determine whether TLR 210 
polymorphisms confer susceptibility to RA and/or influence the clinical features. This 211 
study, that included a TLR8 polymorphism (rs5741883) in the non-coding upstream 212 
region of the gene, did not find a clear association with any of the variants analyzed [5]. 213 
However, the lack of a statistically significant amount of data precluded the possibility of 214 
reaching conclusive results. Another study that genotyped RA patients for 22 215 
polymorphisms in 7 TLR genes concluded that only rs5741883 showed a moderate 216 
association with rheumatoid factor positivity [23]. To avoid SNP preselection bias, we 217 
conducted a systematic and high-throughput study by sequencing all coding and flanking 218 
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regions of nine TLR genes in 66 patients. The selected TLR8 polymorphism, M1V, was 219 
further studied in a larger cohort of 402 patients to validate our data. 220 
The SNP that leads to M1V variant (rs3764880, A>G) has been previously studied in 221 
patients with tuberculosis, showing that the major allele A was associated with 222 
susceptibility to this infectious disease [30]. In line with this, another report showed that 223 
the G allele conferred a significant protective effect to HIV-positive adults regarding 224 
progression of the disease [31]. Furthermore, TLR8 signaling results in the induction of 225 
proinflammatory cytokines [15]. Consistently, we found that GG genotype carriers 226 
produced significantly lower levels of inflammatory cytokines, IL1, IL6 and TNF, 227 
when blood mononuclear cells were stimulated with TLR8 agonists. A>G change 228 
eliminates the start codon and provokes the use of the next in-frame ATG, which 229 
generates a deletion of the first three amino acids of TLR8, giving rise to TLR8v2 230 
isoform. We showed that G allele carriers develop a less severe disease and reduce the 231 
need for therapy. A likely mechanistic explanation might be in the stability of TLR8 232 
mRNA. Transfection experiments with both A and G allelic variants of TLR8 showed 233 
that the amount of the G variant mRNA was significantly lower, suggesting that this 234 
mRNA may be less stable [32]. A similar polymorphism has been described in the vitamin 235 
D receptor gene [33]. A T>C change at the initiation codon gives rise to a shorter isofom 236 
lacking the first three amino acids, which has functional consequences due to differences 237 
in the transcriptional capacity of both alleles. Although a scenario where the G allele 238 
correlates with a lower inflammatory activity is consistent with our data, it has also been 239 
described that the same allele is more efficient than the A allele in promoting activation 240 
of the NFB proinflammatory pathway [32]. This result was obtained by cotransfecting 241 
cells with a luciferase reporter construct and the A/G allelic variants of TLR8. Our results 242 
are based on in vivo data in a large cohort of RA patients.  243 
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In conclusion, our study suggests that the presence of the TLR8 allelic variant M1V, may 244 
be associated with a reduced severity of rheumatoid arthritis in a Caucasian Spanish 245 
population. Replication of these results in other cohorts of patients, including populations 246 
with different genetic background, would strengthen the prognostic value of M1V variant 247 
in patients with RA.   248 
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Figure Legends 346 
Fig 1. Association of the M1V variant of TLR8 with disease severity in a cohort of 347 
402 patients with RA. (A) Carriers of the indicated genotypes were distributed in regards 348 
to presence of serum ACCP and RF, need of surgery, and clinical remission. ACCP, anti-349 
cyclic citrullinated protein antibodies; RF, rheumatoid factor. Box plot showing the 350 
association between the total number of disease-modifying antirheumatic drugs 351 
(DMARDs) (B), or biologics (C) that each patient has received during the course of the 352 
disease, and TLR8 genotypes in RA patients.  353 
Fig 2. TLR 8 activity according to TLR8 genotypes in patients with RA. (A-C) TLR8 354 
activity was assessed by measuring intracellular proinflammatory cytokine production 355 
following treatment of circulating monocytes with ssRNA40, a TLR8 specific agonist. 356 
Cytokine and CD14 co-staining with specific antibodies was used to reveal the expression 357 
of cytokines in monocytes by using flow cytometry. Values represent the difference 358 
between the percentage of cells expressing the cytokine with and without treatment with 359 
the TLR8 agonist (delta).  360 
 361 
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